Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy

Guin, Claudia H D Le; Metz, K.; Lehmann, Nils; Kreis, Stefan; Bornfeld, Norbert; Lohmann, Dietmar; Zeschnigk, Michael

doi:10.1080/1354750x.2018.1517827

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients may benefit from a dedicated schedule of systemic closer surveillance for metastases, early treatment of focal liver lesions and enrollment into adjuvant systemic therapy clinical trials [28,29]. FNAB requires local or general anesthesia and, although over the years this has become an effective and safe procedure in experienced hands [19,30], it is not without complications [10,19]. FNABrelated complications can be distinguished as minor and major.…”

Section: Introductionmentioning

confidence: 99%

Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?

Foti,

Inì,

Broggi

et al. 2023

Cancers

View full text Add to dashboard Cite

Histopathologically, uveal melanomas (UMs) can be classified as spindle cell, mixed cell and epithelioid cell type, with the latter having a more severe prognosis. The aim of our study was to assess the correlation between the apparent diffusion coefficient (ADC) and the histologic type of UMs in order to verify the role of diffusion-weighted magnetic resonance imaging (DWI) as a noninvasive prognostic marker. A total of 26 patients with UMs who had undergone MRI and subsequent primary enucleation were retrospectively selected. The ADC of the tumor was compared with the histologic type. The data were compared using both one-way analysis of variance (ANOVA) (assessing the three histologic types separately) and the independent t-test (dichotomizing histologic subtypes as epithelioid versus non-epithelioid). Histologic type was present as follows: the epithelioid cell was n = 4, and the spindle cell was n = 11, the mixed cell type was n = 11. The mean ADC was 1.06 ± 0.24 × 10−3 mm2/s in the epithelioid cells, 0.98 ± 0.19 × 10−3 mm2/s in the spindle cells and 0.96 ± 0.26 × 10−3 mm2/s in the mixed cell type. No significant difference in the mean ADC value of the histopathologic subtypes was found, either when assessing the three histologic types separately (p = 0.76) or after dichotomizing the histologic subtypes as epithelioid and non-epithelioid (p = 0.82). DWI-ADC is not accurate enough to distinguish histologic types of UMs.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?

Foti,

Inì,

Broggi

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Prescher already reported a 50% metastases rate in patients with monosomy 3 after 3 years 17 . Le Guin showed a significant association between monosomy 3 and tumour-related survival not only in patients after enucleation but also in the subgroup after brachytherapy 12 .…”

Section: Discussionmentioning

confidence: 98%

Uveal melanoma - testing of abnormalities of chromosome 3 and 8 in the Czech Republic

et al. 2020

View full text Add to dashboard Cite

The aim of this cytogenetic study is to confirm the significance of chromosome 3 loss (monosomy 3) and of the gain of chromosome 8 as prognostic markers in histopathological samples of enucleated eyes with uveal melanoma in the Czech population. Methods. This is a retrospective study of 52 enucleated eyes. Chromosome 3 and 8 status were tested by CISH, and in a few samples FISH was used. The correlation between monosomy 3 and gain of chromosome 8 and clinical features (histopathological type, size of the tumour) were evaluated. A follow up for the detection of metastases was conducted in all patients. The statistical significance of chromosomal abnormalities as a prognostic factor for the development of metastases was calculated. Results. There were 52 patients, 27 men (51.9%) and 25 women (48.1%) enrolled in our study group. The mean age was 63 ± 14 years. Loss of the one copy of chromosome 3 (monosomy 3) was detected in 26 (50.0%) patients, monosomy 8 was present in 34.6% of patients with monosomy 3. After 5 years there were no metastases in 82% of patients without monosomy 3 as opposed to 40% of patients with monosomy 3. We confirmed a statistically significant association between progression free survival (PFS) and the presence of monosomy 3 (P=0.017). The association between PFS and gain of chromosome 8 was significant as well (0.010). Conclusions. Our data showed the association of progression-free survival with the presence of monosomy 3 in uveal melanomas. We provided a good prognostic value of monosomy 3 in uveal melanoma.

show abstract

“…Research still lacks clarity on whether different treatment methods impact psychosocial well-being [10,12,[14][15][16][17][18][19][20][21]. This is important, especially if specific treatments can be interrelated with the nature of the tumor or a certain diagnosis [7,46,47]. In our study, we controlled for enucleation to adjust for potential impairments associated with this treatment (loss of eye and sight, cosmetic changes etc.…”

Section: Psychological Distress and Utilization Of Psychooncological mentioning

confidence: 99%

Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: The risk of metastases in uveal melanoma can accurately be estimated through genetic analysis of the tumor. A growing number of patients decide to receive information on their prognosis, although this can be extremely burdensome. Studies on the psychosocial impact of testing are sparse. The objective of this study was to examine traits of patients opting for prognostication, to investigate its psychosocial impact and the use of psychooncological services over time. We further examined characteristics of patients utilizing these services and risk factors of prolonged psychological distress. Design and methods: This study is a non-randomized controlled prospective clinical observational trial. Patients availing for prognostication formed the test group, while those who opted out constituted the observational group. The psychosocial impact of genetic testing was assessed with the following variables: resilience, social support, fear of tumor progression, depression, general distress, health-related quality of life, estimation of the perceived risk, and the utilization of psycho-oncological interventions. Data were assessed at five different time points over a period of 12 months. We applied binary logistic regression analysis, multiple linear regressions and a mixed model. Results: Of 175 patients, 63 decided to obtain prognostic information. Treatment method (enucleation > brachytherapy), lower social support and higher general distress could significantly predict patient's choice for prognostic testing. After result announcement, perceived risk of metastases was significantly increased in patients with poor prognosis, while it decreased in those with good prognosis. Overall, a significant decrease over time appeared concerning fear of progression, general distress, depression and anxiety. Mental quality of life increased over time. The utilization of psycho-oncological interventions increased significantly after prognostication; however, this was equivalent in the test and observational groups. Female sex, higher general distress and higher anxiety predicted greater use of psycho-oncological interventions. Discussion: Availing of prognostic testing is not associated with poorer subsequent psychological well-being. It rather may help to alleviate distress and promote a more realistic risk perception. However, psychological support should be available to all patients, independent of prognosis and treatment, especially considering that patients with low social support and high distress increasingly opt for prognostication.

show abstract

Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy

Cited by 5 publications

References 19 publications

Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?

Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?

Uveal melanoma - testing of abnormalities of chromosome 3 and 8 in the Czech Republic

Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study

Contact Info

Product

Resources

About